161 related articles for article (PubMed ID: 15158344)
1. Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C.
Hofer H; Osterreicher C; Jessner W; Penz M; Steindl-Munda P; Wrba F; Ferenci P
J Hepatol; 2004 Jun; 40(6):1018-22. PubMed ID: 15158344
[TBL] [Abstract][Full Text] [Related]
2. Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major.
Sievert W; Pianko S; Warner S; Bowden S; Simpson I; Bowden D; Locarnini S
Am J Gastroenterol; 2002 Apr; 97(4):982-7. PubMed ID: 12003436
[TBL] [Abstract][Full Text] [Related]
3. Assessment of selected clinical factors as predictors of response to combined interferon-alpha plus ribavirin therapy among patients with chronic hepatitis C.
Kryczka W; Zarebska-Michaluk D; Chrapek M
Med Sci Monit; 2003 Aug; 9 Suppl 3():32-5. PubMed ID: 15156609
[TBL] [Abstract][Full Text] [Related]
4. Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients.
Fujita N; Horiike S; Sugimoto R; Tanaka H; Iwasa M; Kobayashi Y; Hasegawa K; Ma N; Kawanishi S; Adachi Y; Kaito M
Free Radic Biol Med; 2007 Feb; 42(3):353-62. PubMed ID: 17210448
[TBL] [Abstract][Full Text] [Related]
5. Iron overload in patients with chronic hepatitis C virus infection: clinical and histological study.
Silva IS; Perez RM; Oliveira PV; Cantagalo MI; Dantas E; Sisti C; Figueiredo-Mendes C; Lanzoni VP; Silva A; Ferraz ML
J Gastroenterol Hepatol; 2005 Feb; 20(2):243-8. PubMed ID: 15683427
[TBL] [Abstract][Full Text] [Related]
6. [The effect of iron depletion on the response to interferon treatment in patients with chronic hepatitis C. Pilot study].
Ortiz V; Olaso V; López Viedma B; Córdoba J; Molina JM; Lainez B; Pastor M; Berenguer J
Gastroenterol Hepatol; 1999 Mar; 22(3):122-6. PubMed ID: 10228321
[TBL] [Abstract][Full Text] [Related]
7. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
[TBL] [Abstract][Full Text] [Related]
8. State of the iron metabolism in patients with chronic hepatitis C type C does not influence antiviral treatment with interferon and ribavirin.
Jurczyk K; Karpińska E; Wawrzynowicz-Syczewska M; Morańska I; Noceń I; Chlubek D; Boroń-Kaczmarska A
Hepatogastroenterology; 2008; 55(82-83):557-61. PubMed ID: 18613407
[TBL] [Abstract][Full Text] [Related]
9. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
[TBL] [Abstract][Full Text] [Related]
10. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
[TBL] [Abstract][Full Text] [Related]
11. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
[TBL] [Abstract][Full Text] [Related]
12. Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy.
El-Zayadi AR; Attia M; Badran HM; El-Tawil A; Zalata K; Barakat E; Selim O; El-Nakeeb A; Saied A
Liver Int; 2005 Aug; 25(4):746-51. PubMed ID: 15998425
[TBL] [Abstract][Full Text] [Related]
13. Hepatic iron stainings in chronic hepatitis C patients with low HCV RNA levels: a predictive marker for IFN therapy.
Akiyoshi F; Sata M; Uchimura Y; Suzuki H; Tanikawa K
Am J Gastroenterol; 1997 Sep; 92(9):1463-6. PubMed ID: 9317063
[TBL] [Abstract][Full Text] [Related]
14. Ribavirin in the treatment of hepatitis C.
Abonyi ME; Lakatos PL
Anticancer Res; 2005; 25(2B):1315-20. PubMed ID: 15865084
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
[TBL] [Abstract][Full Text] [Related]
16. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C.
Fujita N; Sugimoto R; Urawa N; Araki J; Mifuji R; Yamamoto M; Horiike S; Tanaka H; Iwasa M; Kobayashi Y; Adachi Y; Kaito M
J Gastroenterol Hepatol; 2007 Nov; 22(11):1886-93. PubMed ID: 17914965
[TBL] [Abstract][Full Text] [Related]
17. Steatosis as a predictive factor for treatment response in patients with chronic hepatitis C.
Antúnez I; Aponte N; Fernández-Carbia A; Rodríguez-Perez F; Toro DH
P R Health Sci J; 2004 Jun; 23(2 Suppl):57-60. PubMed ID: 16929588
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.
Roche B; Sebagh M; Canfora ML; Antonini T; Roque-Afonso AM; Delvart V; Saliba F; Duclos-Vallee JC; Castaing D; Samuel D
Liver Transpl; 2008 Dec; 14(12):1766-77. PubMed ID: 19025933
[TBL] [Abstract][Full Text] [Related]
19. [Serum iron parameters in chronic hepatitis C patients and comparison of the results before and during antiviral treatment].
Bolewska B; Wojtacha A; Juszczyk J; Przedwojewski M
Pol Merkur Lekarski; 2005 May; 18(107):552-5. PubMed ID: 16161954
[TBL] [Abstract][Full Text] [Related]
20. Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin.
Fujita N; Kaito M; Kai M; Sugimoto R; Tanaka H; Horiike S; Konishi M; Iwasa M; Watanabe S; Adachi Y
J Viral Hepat; 2006 Jul; 13(7):441-8. PubMed ID: 16792537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
